Allianz Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Allianz Asset Management's XBI Position: Q2 2020 in Review
Allianz Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2020, closing a stake of 33,432 shares — an estimated $2.59M sold.
Allianz Asset Management first reported a position in XBI in Q1 2015 and held it in 8 quarters. The position peaked at $5.91M in Q3 2019. 525 funds tracked by Wall St. Rank hold XBI as of Q2 2020.
- Allianz Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2020 after selling out during the quarter.
- Allianz Asset Management sold 33,432 State Street SPDR S&P Biotech ETF shares in Q2 2020, an estimated $2.59M.
- Allianz Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2015 and held it in 8 quarters.
- Allianz Asset Management's State Street SPDR S&P Biotech ETF position peaked at $5.91M in Q3 2019.
- 525 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2020.
Based on Allianz Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.